* If you want to update the article please login/register
Purpose of Review The aim of this essay is to outline migraine activism as an essential tool to advance headache medicine research. Summary This summary includes the most recent advocacy efforts to implement legislation that may improve migraine care, increase the field of headache research, and reduce the burden of migraines.
Source link: https://doi.org/10.1007/s11916-022-01059-1
Background The conventional treatment of occipital migraine surgery includes three separate surgical incisions in the posterior neck to decompress the greater occipital nerves, reduced occipital nerves, and third occipital nerves. For decompression of all six occipital nerves, we needed to find a single, vertical midline incision system. Results The GON and TON were found at 3. 5 and 6. 2 cm, respectively, inferior to a line bisecting the external auditory canal and 1. 5 cm lateral to the midline, according to the midline's midline. The LON was traced as 6-cm inferior and 6. 5-cm medial to a line bisecting the EAC in the plane just above the deep cervical fascia's investing layer until the sternocleidomastoid's posterior border was encountered. All six occipital nerves in migraine surgery can be identified and decompressed by a single midline incision technique.
Source link: https://doi.org/10.1186/s12893-022-01675-z
Lasmiditan, a novel selective serotonin 1F receptor agonist, is expected to provide medical relief to Chinese migraine sufferers. The CENTURION study is a multi-country, placebo-controlled phase 3 research designed to determine the first attack efficacy and the consistency of lasmida in acute migraine treatment. This subpopulation review assembled Chinese patients'u2019 results from the primary cohort and an additional extended enrollment cohort that were not reported before. This is the first review of lasmiditanu2019's efficacy and safety in Chinese patients with migraine, and it seeks to have pertinent data for Chinese physicians. Conclusions In total, 281 Chinese patients were treated for at least one migraine attack. Both doses of lasmiditan showed improvement in pain relief at 2 h after the first attack, with lasmiditan 200 mg showing nominal significance.
Source link: https://doi.org/10.1007/s40120-022-00369-1
Background Erenumab is a completely human monoclonal antibody and a highly active, first-in-class calcitonin gene-related peptide receptor inhibitor approved for migraine prevention in adults. In real-life scenarios in the UAE, the primary study aim was to describe the use of erenumab in patients with persistent migraine or episodic migraine. Similar decreases in MHD and MSMD, as well as clinical success in CM or EM were seen with erenumab monotherapy or erenumab add-on therapy, with or without dose escalation and dose increase to 140 mg subgroups. Patients prescribed erenumab in the UAE achieved clinically significant decreases in MHD and MSMD at both time points.
Source link: https://doi.org/10.1186/s12883-022-02710-5
The pathophysiology of migraine as a headache disorder is also uncertain. Diffusion tensor imaging has greatly enhanced our understanding of brain microstructure in this disorder. Here, we set out to investigate DTI studies in migraine and determining the sources of heterogeneity by investigating diffusion parameter changes related to clinical characteristics and migraine subtypes. In addition, migraine-related to depressive/anxiety symptoms revealed dramatic changes in the corpus callosum, internal capsule, and superior longitudinal fasciculus. No significant WM microstructural differences were found between migraine patients with and without aura. Conclusions: Inconsistency among chronic and episodic migraine sufferers revealed inconsistency across studies. These changes may reveal neuronal injury and neuronal plasticity mechanisms, either as a result of migraine stimulations that occur during migraine cycle or as a compensatory response to pain in chronic migraine. Longitudinal studies using advanced modalities may shed new light on migraine subtypes'underlying microstructural variations.
Source link: https://doi.org/10.1007/s11682-022-00690-1
Atogepant is a potent, selective, orally available antagonist of the CGRP receptor that has been approved as a preventive treatment of episodic migraine. Patients treated with atogepant with either the daily dose of 10 mg, 30 mg, or 60 mg were significantly more than placebo during the 12-week treatment period. There were no differences in the occurrence of AEs and drug withdrawal among atogepant and placebo groups; there were no differences in the occurrence of AEs and opioid withdrawal due to AEs and drug withdrawal due to AEs between atogepant and placebo groups. Patients treated with atogoguepant at 30 mg/day or placebo exhibited constipation more often than placebo. Atogepant treatment at a daily dose of 60 mg was attributed to a greater risk of constipation and nausea than placebo. Atogepant is an inexpensive and generally well-tolerated medication for the prevention of episodic migraine in adults.
Source link: https://doi.org/10.1007/s40120-022-00370-8
In the general population, there is growing evidence for the efficacy and safety of acupuncture for migraine treatment, but there are no reports on acupuncture during pregnancy. With this retrospective review, we wanted to see if there is a correlation between acupuncture treatment and preterm delivery and side effects of therapy. 68 women with migraine, 47 of whom responded to a questionnaire on acupuncture safety within six weeks of delivery, were the initial study group. According to our preliminary results, acupuncture may be safe during pregnancy in women with migraine.
Source link: https://doi.org/10.1007/s10072-022-06201-w
The objective of this review was to determine the safety of various doses of the onabotulinumtoxinA therapy in patients with chronic migraines. Methods This is a retrospective paired comparison study of patients with chronic migraine who received at least three rounds of 150 units of onabotulinumtoxinA and at least three rounds of 200 units of onabotulinumtoxinA. After an increase in the onabotulinumtoxinA dose, respectively, the headache days and severe headache days decreased from 13. 74 and 5. 83 to 11. 01 b. 01. 01 & 4. 82 days. The 200 units were better than the 150 units of the onabotulinumtoxinA unit treatment, but the patients continued to receive the higher dose of onabotulinumtoxinA. Conclusion We found that the increase in the onabotulinumtoxinA has been associated with less headache and days of severe headaches.
Source link: https://doi.org/10.1186/s12883-022-02742-x
We prospectively investigated CGRP and PACAP-38 plasma levels in children with migraine during ictal and interictal periods, comparing migraine patients with aura and without aura. Results PACAP-38 and CGRP-36 respectively increased in migraine patients during the ictal and interictal periods of greater than those in controls. Conclusions Our review found almost identical changes in pediatric migraine CGRP and PACAP, indicating that CGRP and PACAP-38 can collaborate to play a vital role in pediatric migraine. CGRP higher CGRP were found in the ictal phase than in the interictal phase, with greater aura group than without aura group, suggesting that CGRP may play a role in pain and aura formation.
Source link: https://doi.org/10.1186/s10194-022-01435-7
However, real-life results are still lacking and ignorant of the effect of galcanezumab on those key migraine factors that are directly contributing to migraine prevention. Herein we present the latest medical case from an Italian real-world setting using galcanezumab in patients with migraines with previous unsuccessful preventive treatments. Methods Forty-three patients with migraine and failure of at least three migraine prevention medication classes were enrolled in monthly galcanezumab 120 mg s. c. , according to this study, patients underwent extensive interviews to determine disease prevalence and severity. Per month, headaches decreased from 20. 56 to 7. 44 and 6. 37 headache days per month, respectively, during the third and sixth administrations of monthly galcanezumab 120 mg s. c. , respectively. In addition, a significant rise in headache frequency and duration as well as in scores assessing migraine-related disability and impact, depressive and anxious symptoms, and pain catastrophizing were found.
Source link: https://doi.org/10.1186/s10194-022-01436-6
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions